

Author Index Volume 15 (2015)

The issue number is given in front of the pagination

- Abdel Salam, R., N. El-Badry, A. Rizk, A. El-Sedfy, N. Kamel and E. El-Abd, Expression of ECM1 and MMP-2 in follicular thyroid lesions among Egyptians (4) 441–458
- Abhishek, A., see Sankhwar, M. (4) 349–355
- Adrados, M., see Zapatero, A. (1) 41–46
- Ahmad, M.K., see Singh, P.K. (2) 125–131
- Ahmad, R., see Danish, Q. (5) 619–633
- Ahmed, A.A., see Aljada, A. (5) 653–661
- Al Dubayee, M., see Aljada, A. (5) 653–661
- Al-Aqeel, S.M., see Aljada, A. (5) 653–661
- Al-Bawab, A., see Aljada, A. (5) 653–661
- Aljada, A., A.M. Saleh, S.M. Al-Aqeel, H.B. Shamsa, A. Al-Bawab, M. Al Dubayee and A.A. Ahmed, Quantification of insulin receptor mRNA splice variants as a diagnostic tumor marker in breast cancer (5) 653–661
- Almomani, N., see Mhaidat, N.M. (2) 197–203
- Alvares, L.E., see Schussel, J.L. (1) 11–17
- Alzoubi, K.H., see Mhaidat, N.M. (2) 197–203
- Amara, S., I. Chaar, M. Khiari, D. Ounissi, M. Weslati, R. Boughriba, A.B. Hmida and S. Bouraoui, Stromal cell derived factor-1 and CXCR4 expression in colorectal cancer promote liver metastasis (6) 869–879
- Andrabi, K.I., see Khan, M.S. (4) 459–465
- Apergis, G., see Vlachostergios, P.J. (6) 725–734
- Aravantinos, G., A. Isaakidou, T. Karantanos, A. Sioziou, G.E. Theodoropoulos, D. Pektasides and M. Gazouli, Association of CD133 polymorphisms and response to bevacizumab in patients with metastatic colorectal cancer (6) 843–850
- Arellano, R., see Zapatero, A. (1) 41–46
- Asadi, J., see Ghanbari, R. (2) 189–195
- Askeland, E.J., V.A. Chehval, R.W. Askeland, P.G. Fosso, Z. Sangale, N. Xu, S. Rajamani, S. Stone and J.A. Brown, Cell cycle progression score predicts metastatic progression of clear cell renal cell carcinoma after resection (6) 861–867
- Askeland, R.W., see Askeland, E.J. (6) 861–867
- Austin, J., see Brentnall, A.R. (5) 669–675
- Ayremlou, N., H. Mozdarani, S.J. Mowla and A. Delavari, Increased levels of serum and tissue miR-107 in human gastric cancer: Correlation with tumor hypoxia (6) 851–860
- Bager, C.L., N. Willumsen, D.J. Leeming, V. Smith, M.A. Karsdal, D. Dornan and A.C. Bay-Jensen, Collagen degradation products measured in serum can separate ovarian and breast cancer patients from healthy controls: A preliminary study (6) 783–788
- Bai, G., see Chen, G. (6) 833–841
- Bai, J., Z. Zhang, X. Li and H. Liu, MicroRNA-365 inhibits growth, invasion and metastasis of malignant melanoma by targeting NRPI expression (5) 599–608
- Bai, L., see Liu, Q. (1) 65–78
- Baltazar, S., see Gutiérrez-Monreal, M.A. (5) 699–705
- Bansal, N., A. Gupta and S.N. Sankhwar, Proteometabolomics of bladder cancer: Current and future prospects (4) 339–348
- Barros-Angueira, F., see Pérez-Sayáns, M. (1) 19–26
- Bay-Jensen, A.C., see Bager, C.L. (6) 783–788
- Benitez, J., see Krivokuca, A. (6) 775–781
- Besse, B., see Raphael, J. (2) 151–156
- Bhuyan, C., see Sarma, A. (4) 501–505
- Bialek, S., see Bobrowska-Korczak, B. (2) 133–142
- Bian, H., see Han, L. (3) 289–297
- Billiot, F., see Raphael, J. (2) 151–156
- Bloodsworth, P., see Gul, S. (5) 551–557
- Bobrowska-Korczak, B., D. Skrajnowska, A. Tokarz, S. Bialek and E. Jezierska, Effect of zinc and polyphenols supplementation on antioxidative defense mechanisms and the frequency of microsatellite instability in chemically-induced mammary carcinogenesis in the rat (2) 133–142
- Bogatyuk, M.V., see Kaigorodova, E.V. (2) 143–150

- Bogra, J., see Singh, P.K. (2) 125–131
- Boljevic, I.Z., see Malisic, E.J. (5) 685–691
- Boughriba, R., see Amara, S. (6) 869–879
- Bouraoui, S., see Amara, S. (6) 869–879
- Brankovic-Magic, M., see Krivokuca, A. (6) 775–781
- Brentnall, A.R., N. Vasiljevic, D. Scibior-Bentkowska, L. Cadman, J. Austin, J. Cuzick and A.T. Lorincz, HPV33 DNA methylation measurement improves cervical pre-cancer risk estimation of an HPV16, HPV18, HPV31 and *EPB41L3* methylation classifier (5) 669–675
- Brown, J.A., see Askeland, E.J. (6) 861–867
- Bukhari, S., see Danish, Q. (5) 619–633
- Cadman, L., see Brentnall, A.R. (5) 669–675
- Cao, W., see Cao, X. (6) 717–723
- Cao, X., R. Zhao, Q. Chen, Y. Zhao, B. Zhang, Y. Zhang, J. Yu, G. Han, W. Cao, J. Li and X. Chen, MALAT1 might be a predictive marker of poor prognosis in patients who underwent radical resection of middle thoracic esophageal squamous cell carcinoma (6) 717–723
- Cao, Z.A., see Sonkin, D. (1) 79–87
- Cardineau, G.A., see Gutiérrez-Monreal, M.A. (5) 699–705
- Ceylan, K., see Kaynar, M. (3) 317–323
- Chaar, I., see Amara, S. (6) 869–879
- Chandra, G., see Singh, P.K. (2) 125–131
- Chao, T.-C., see Lee, Y.-T. (6) 815–822
- Chehval, V.A., see Askeland, E.J. (6) 861–867
- Chen, D., see Dou, X. (2) 181–188
- Chen, G., Q. Xue, J. Li, T. Gao, Q. Sun and G. Bai, Anticancer activity of recombinant Sival protein in human nasopharyngeal carcinoma cell line CNE-2 (6) 833–841
- Chen, K., see Lian, L. (6) 899–907
- Chen, N., see Wang, R. (1) 27–32
- Chen, Q., see Cao, X. (6) 717–723
- Chen, R., see Zheng, C. (6) 889–897
- Chen, S., see Zheng, H. (5) 525–534
- Chen, X., see Cao, X. (6) 717–723
- Chen, X., see He, Y. (5) 645–651
- Chen, Y., see Wang, Y. (5) 635–643
- Chen, Y.-Z., see Li, Y.-S. (4) 375–380
- Chen, Z., H. Wu, S. Huang, W. Li, S. Zhang, P. Zheng, X. Zhou, W. Liu and D. Zhang, Expression of BNIP3 and its correlations to hypoxia-induced autophagy and clinicopathological features in salivary adenoid cystic carcinoma (4) 467–475
- Chen, Z.H., see Wu, Z.Y. (5) 535–542
- Cheng, G., see Shan, L. (1) 47–56
- Cheng, W., see Li, H. (6) 807–814
- Cheng, Z., see Ouyang, H. (4) 477–484
- Chiou, T.-J., see Lee, Y.-T. (6) 815–822
- Choi, S.H., K.S. Jang and M.S. Chung, Bilateral granulomatous mastitis with a different etiology (3) 333–338
- Christudass, C.S., see Maragh, S. (6) 763–773
- Chung, M.S., see Choi, S.H. (3) 333–338
- Ciftci, R., see Kilic, L. (4) 405–411
- Clancy, C., M.R. Joyce and M.J. Kerin, The use of circulating microRNAs as diagnostic biomarkers in colorectal cancer (2) 103–113
- Conde, A.C., see Zapatero, A. (1) 41–46
- Cui, C., see Zhao, Y. (5) 677–683
- Cui, J., see Wang, X. (5) 663–668
- Cui, J.-L., see Hou, Y.-C. (5) 567–573
- Cui, J.-L., see Xie, X.-M. (3) 259–265
- Cuzick, J., see Brentnall, A.R. (5) 669–675
- Dai, S.-L., J. Zhou, C. Pan, G. Huang, Z.-L. Shi, S.-Y. Yang and K.-X. Yang, Prognostic value of microRNA-145 in patients with various cancers: A meta-analysis (4) 507–513
- Dai, Z., see Wang, T. (5) 543–550
- Danish, Q., T.A. Mokhdomi, S. Bukhari and R. Ahmad, The ensemble of genetic factors and angiogenic signals via VEGF receptors in lung cancer progression (5) 619–633
- Das, D., see Sarma, A. (4) 501–505
- de Almeida, M.R., see Pérez-Sayáns, M. (1) 19–26
- de la Luz Martínez-Fierro, M., see Luna-Aguirre, C.M. (3) 299–310
- de Oliveira, B.V., see Schussel, J.L. (1) 11–17
- de Vidales, C.M., see Zapatero, A. (1) 41–46
- Delavari, A., see Ayremloou, N. (6) 851–860
- Deng, J.-Y., see Hou, Y.-C. (5) 567–573
- Deng, J.-Y., see Xie, X.-M. (3) 259–265
- Dikaiakos, P., M. Gazouli, S. Rizos, G. Zografos and G.E. Theodoropoulos, Evaluation of genetic variants in miRNAs in patients with colorectal cancer (2) 157–162
- Ding, W., see Jiang, Z. (4) 381–389
- Ding, Y., see Shan, L. (1) 47–56
- Dong, Q.-P., see Xie, X.-M. (3) 259–265
- Dornan, D., see Bager, C.L. (6) 783–788
- Dou, X., R. Wang, X. Meng, H. Yan, S. Jiang, K. Zhu, X. Xu, D. Chen, X. Song and D. Mu, The prognostic role of TCF4 expression in locally advanced rectal cancer patients treated with neoadjuvant chemoradiotherapy (2) 181–188
- Du, J.L., see Wu, Z.Y. (5) 535–542

- Du, Z., see Wang, Y. (2) 171–180
 Duan, F., see Xia, Z. (5) 707–716
 Duan, L., see Sun, P. (4) 391–396
 Duranyildiz, D., see Kilic, L. (4) 405–411
 Dworzecka, U., see Mazurek, A. (4) 515–524
 Dziki, A., see Kabzinski, J. (4) 413–423
 Dziki, L., see Kabzinski, J. (4) 413–423
- Ehsan, N., see Gul, S. (5) 551–557
 El-Abd, E., see Abdel Salam, R. (4) 441–458
 El-Badry, N., see Abdel Salam, R. (4) 441–458
 El-Sedfy, A., see Abdel Salam, R. (4) 441–458
 Endou, H., see Yanagisawa, N. (4) 365–374
 Erdem, M.G., see Kilic, L. (4) 405–411
 Erkut, N., A. Mentese, H.M. Ozbas, A. Sumer, A. Orem, M. Topbas and M. Sonmez, The indicator of hypoxia in acute leukemia: Ischemia-modified albumin (5) 559–565
- Faheem, M., see Gul, S. (5) 551–557
 Fan, K., see Tian, T. (4) 425–432
 Fan, Z., see He, Q. (6) 823–831
 Fang, S., see Sun, M. (1) 33–40
 Fanton, C., see Sonkin, D. (1) 79–87
 Farace, F., see Raphael, J. (2) 151–156
 Feng, Y., see Wang, Y. (5) 635–643
 Fosso, P.G., see Askeland, E.J. (6) 861–867
 Franklin, O., D. Öhlund, C. Lundin, M. Öman, P. Naredi, W. Wang and M. Sund, Combining conventional and stroma-derived tumour markers in pancreatic ductal adenocarcinoma (1) 1–10
 Fu, H., see Wang, Y. (5) 635–643
- Gao, J., see Wei, Y. (3) 235–248
 Gao, T., see Chen, G. (6) 833–841
 Gao, T., see Gu, W. (3) 249–258
 Gao, Y., see Wang, Y. (2) 171–180
 García-García, A., see Pérez-Sayáns, M. (1) 19–26
 Garlet, G.P., see Schussel, J.L. (1) 11–17
 Garza-Veloz, I., see Luna-Aguirre, C.M. (3) 299–310
 Gazouli, M., see Aravantinos, G. (6) 843–850
 Gazouli, M., see Dikaiakos, P. (2) 157–162
 Gburek, J., see Kilar, E. (1) 99–102
 Ghanbari, R., N. Mosakhani, J. Asadi, N. Nourae, S.J. Mowla, H. Poustchi, R. Malekzadeh and S. Knuutila, Decreased expression of fecal miR-4478 and miR-1295b-3p in early-stage colorectal cancer (2) 189–195
 Ghorbani, F., see Parsafar, S. (4) 397–403
 Gibilaro, E., see Vlachostergios, P.J. (6) 725–734
 Giglok, M., see Mazurek, A. (4) 515–524
 Goktas, S., see Kaynar, M. (3) 317–323
 Gołąb, K., see Kilar, E. (1) 99–102
 Gomez-Almaguer, D., see Luna-Aguirre, C.M. (3) 299–310
 Gong, F.-R., see Lian, L. (6) 899–907
 Gong, G., see Zhou, J. (3) 325–331
 Gong, I.Y., see Raphael, J. (2) 151–156
 González, M., see Zapatero, A. (1) 41–46
 Gonzalez-Llano, O., see Luna-Aguirre, C.M. (3) 299–310
 Goufman, E.I., V.N. Iakovlev, N.B. Tikhonova and A.E. Lokshin, Quantification of autoantibodies to plasminogen in plasma of patients with cancer (3) 281–287
 Gu, J., see Wang, X. (5) 663–668
 Gu, W., T. Gao, Y. Sun, X. Zheng, J. Wang, J. Ma, X. Hu, J. Li and M. Hu, lncRNA expression profile reveals the potential role of lncRNAs in gastric carcinogenesis (3) 249–258
 Gu, X., see Tian, T. (4) 425–432
 Gul, M., see Kaynar, M. (3) 317–323
 Gul, S., S. Murad, N. Ehsan, P. Bloodsworth, A. Sultan and M. Faheem, Transcriptional up-regulation of BMP-4 and BMPRII genes in the peripheral blood of breast cancer patients: A pilot study (5) 551–557
 Guo, X., see Han, L. (3) 289–297
 Guo, X.-B., see Li, Y.-S. (4) 375–380
 Guo, Y., see Ouyang, H. (4) 477–484
 Guo, Y., see Tian, T. (4) 425–432
 Guo, Z., see Ouyang, H. (4) 477–484
 Guo, Z., see Xia, Z. (5) 707–716
 Gupta, A., see Bansal, N. (4) 339–348
 Gupta, R., see Singh, P.K. (2) 125–131
 Gutierrez-Aguirre, C.H., see Luna-Aguirre, C.M. (3) 299–310
 Gutiérrez-Monreal, M.A., L. Villela, S. Baltazar, Y. Perfecto-Avalos, G.A. Cardineau and S.-P. Scott, A PER3 polymorphism is associated with better overall survival in diffuse large B-cell lymphoma in Mexican population (5) 699–705
 Gworys, B., see Kilar, E. (1) 99–102
- Hamada, Y., see Miyata, Y. (6) 789–797
 Han, B., R. Xie, S. Wu, L. Li and L. Zhu, A case study on the identification of confounding factors for gene disease association analysis (3) 267–280
 Han, G., see Cao, X. (6) 717–723
 Han, L., X. Guo, H. Bian, Y. Zhou, T. Li and J. Yang, Changed expression and function of P-gp in peripheral blood CD56⁺ cells predicting chemoresistance in non-Hodgkin lymphoma patients (3) 289–297

- Han, S.-G., see Lian, L. (6) 899–907
 Hana, K., see Yanagisawa, N. (4) 365–374
 Hao, J.-J., see Shi, Z.-Z. (6) 755–761
 Hao, X.-S., see Hou, Y.-C. (5) 567–573
 Hao, X.-S., see Xie, X.-M. (3) 259–265
 Hao, Y., see K. Wang, (1) 89–97
 Hatahira, S., see Nakashima, M. (4) 357–364
 Hazarika, M., see Sarma, A. (4) 501–505
 He, G., see Song, Y. (5) 591–597
 He, H., see Wang, X. (5) 663–668
 He, H., see Zhou, J. (3) 325–331
 He, H.-D., see Wang, X.-L. (6) 799–805
 He, Q., B. Peng, D. Zhuang, L. Xiao, L. Zheng, Z. Fan, J. Zhu, B. Xu, C. Xu, J. Zhao, L. Wu, P. Zhou, L. Hou, F. Yu and G. Zhao, Clinicopathological significance of β -tubulin isotype III gene expression in breast cancer patients (6) 823–831
 He, Y., X. Chen, H. Liu, H. Xiao, W.R. Kwapong and J. Mei, Matrix-remodeling associated 5 as a novel tissue biomarker predicts poor prognosis in non-small cell lung cancers (5) 645–651
 Hematti, S., see Parsafar, S. (4) 397–403
 Hennenlotter, J., see Tsaour, I. (3) 311–316
 Hidalgo-Miranda, A., see Luna-Aguirre, C.M. (3) 299–310
 Hiura, K., A. Shiraishi, C. Suzuki, K. Takamura, M. Yamamoto, H. Komori, Y. Watanabe and S. Iwaki-Egawa, MMP-9/ANC score as a predictive biomarker for efficacy of bevacizumab plus platinum doublet chemotherapy in patients with advanced or recurrent non-squamous non-small cell lung cancer (4) 433–440
 Hmida, A.B., see Amara, S. (6) 869–879
 Holash, J., see Sonkin, D. (1) 79–87
 Hollebecque, A., see Raphael, J. (2) 151–156
 Horrigan, K., see Sonkin, D. (1) 79–87
 Hou, L., see He, Q. (6) 823–831
 Hou, Y.-C., J.-Y. Deng, R.-P. Zhang, X.-M. Xie, J.-L. Cui, W.-P. Wu, X.-S. Hao and H. Liang, Evaluating the clinical feasibility: the direct bisulfite genomic sequencing for examination of methylated status of protocadherin10 (PCDH10) promoter to predict the prognosis of gastric cancer (5) 567–573
 Hou, Y.-C., see Xie, X.-M. (3) 259–265
 Hu, M., see Gu, W. (3) 249–258
 Hu, S.X., see Wu, Z.Y. (5) 535–542
 Hu, X., see Gu, W. (3) 249–258
 Huang, B.J., see Wu, Z.Y. (5) 535–542
 Huang, C.M., see Wu, Z.Y. (5) 535–542
 Huang, G., see Dai, S.-L. (4) 507–513
 Huang, K., see Wu, Z.Y. (5) 535–542
 Huang, S., see Chen, Z. (4) 467–475
 Huang, Y., see Wang, Y. (3) 213–218
 Humphreys, E.B., see Maragh, S. (6) 763–773
 Iakovlev, V.N., see Goufman, E.I. (3) 281–287
 Ichinoe, M., see Yanagisawa, N. (4) 365–374
 Iruegas, E.P. see Pérez-Sayáns, M. (1) 19–26
 Isaakidou, A., see Aravantinos, G. (6) 843–850
 Isharwal, S., see Maragh, S. (6) 763–773
 Iwabuchi, T., see Yoshimoto, C. (4) 493–499
 Iwaki-Egawa, S., see Hiura, K. (4) 433–440
 Jaime-Perez, J.C., see Luna-Aguirre, C.M. (3) 299–310
 Jain, A., see Singh, P.K. (2) 125–131
 Jakubauskiene, E., I. Peciuliene, L. Vilys, P. Mocevičius, G. Vilkaitis and A. Kanopka, Gastrointestinal tract tumors and cell lines possess differential splicing factor expression and tumor associated mRNA isoform formation profiles (5) 575–581
 Jang, K.S., see Choi, S.H. (3) 333–338
 Jankovic, R.N., see Malisic, E.J. (5) 685–691
 Janocha, A., see Kilar, E. (1) 99–102
 Jezierska, E., see Bobrowska-Korczak, B. (2) 133–142
 Ji, F., see Wang, T. (5) 543–550
 Ji, Q., see Shan, L. (1) 47–56
 Jia, X., see Wang, Y. (2) 171–180
 Jian, Z.X., see Wu, Z.Y. (5) 535–542
 Jiang, C., see Jiang, Z. (4) 381–389
 Jiang, S., see Dou, X. (2) 181–188
 Jiang, Y.-Y., see Shi, Z.-Z. (6) 755–761
 Jiang, Z., Q. Song, S. Yang, R. Zeng, X. Li, C. Jiang, W. Ding, J. Zhang and Y. Zheng, Serum microRNA-218 is a potential biomarker for esophageal cancer (4) 381–389
 Jiao, S., W. Liu, M. Wu, C. Peng, H. Tang and X. Xie, Nrdp1 expression to predict clinical outcome and efficacy of adjuvant anthracyclines-based chemotherapy in breast cancer: A retrospective study (2) 115–123
 Jiao, X., see Wang, Y. (2) 171–180
 Jin, C., see Zheng, C. (6) 889–897
 Jin, Z., see Zheng, C. (6) 889–897
 Jing, C., see Xia, Z. (5) 707–716
 Joyce, M.R., see Clancy, C. (2) 103–113
 Kabzinski, J., K. Przybylowska, L. Dziki, A. Dziki and I. Majsterek, An association of selected ERCC2 and ERCC5 genes polymorphisms, the level of oxidative DNA damage and its repair efficiency with a risk of colorectal cancer in Polish population (4) 413–423

- Kaigorodova, E.V., M.V. Zavyalova, M.V. Bogatyuk, N.A. Tarabanovskaya, E.M. Slonimskaya and V.M. Perelmuter, Relationship between the expression of phosphorylated heat shock protein beta-1 with lymph node metastases of breast cancer (2) 143–150
- Kalinke, L.P., see Schussel, J.L. (1) 11–17
- Kamel, N., see Abdel Salam, R. (4) 441–458
- Kanazawa, H., see Miyata, Y. (6) 789–797
- Kaneda, G., see Miyata, Y. (6) 789–797
- Kanopka, A., see Jakubauskiene, E. (5) 575–581
- Karabulut, S., see Kilic, L. (4) 405–411
- Karantanos, T., see Aravantinos, G. (6) 843–850
- Karsdal, M.A., see Bager, C.L. (6) 783–788
- Kataki, A.C., see Sarma, A. (4) 501–505
- Kawakami, K., see Nakashima, M. (4) 357–364
- Kaynar, M., M.E. Yildirim, M. Gul, O. Kilic, K. Ceylan and S. Goktas, Benign prostatic hyperplasia and prostate cancer differentiation via platelet to lymphocyte ratio (3) 317–323
- Kerin, M.J., see Clancy, C. (2) 103–113
- Keskin, S., see Kilic, L. (4) 405–411
- Khabour, O.F., see Mhaidat, N.M. (2) 197–203
- Khalili, E., see Naghibalhossaini, F. (3) 227–233
- Khan, M.S., A.A. Pandith, S.R. Masoodi, S.H. Khan, T.A. Rather, K.I. Andrabi and S. Mudassar, Significant association of TP53 Arg72Pro polymorphism in susceptibility to differentiated thyroid cancer (4) 459–465
- Khan, S.H., see Khan, M.S. (4) 459–465
- Khiari, M., see Amara, S. (6) 869–879
- Kilar, E., B. Gworys, T. Skiba, J. Gburek, K. Gołab, A. Janocha and M. Siewiński, Antipapain activity in the serum of patients with breast cancer (1) 99–102
- Kilic, L., I. Yildiz, F.K. Sen, M.G. Erdem, M. Serilmez, S. Keskin, R. Ciftci, S. Karabulut, C. Ordu, D. Duranyildiz and F. Tas, D-dimer and international normalized ratio (INR) are correlated with tumor markers and disease stage in colorectal cancer patients (4) 405–411
- Kilic, O., see Kaynar, M. (3) 317–323
- Kitaura, K., see Miyata, Y. (6) 789–797
- Knuutila, S., see Ghanbari, R. (2) 189–195
- Kobayashi, H., see Yoshimoto, C. (4) 493–499
- Kobayashi, T., see Nakashima, M. (4) 357–364
- Komori, H., see Hiura, K. (4) 433–440
- Krivokuca, A., K. Yanowski, J. Rakobradovic, J. Benitez and M. Brankovic-Magic, *RAD51C* mutation screening in high-risk patients from Serbian hereditary breast/ovarian cancer families (6) 775–781
- Krivokuca, A.M., see Malisic, E.J. (5) 685–691
- Kuehs, U., see Tsaor, I. (3) 311–316
- Kumagai, K., see Miyata, Y. (6) 789–797
- Kumar, V., see Singh, P.K. (2) 125–131
- Kwapong, W.R., see He, Y. (5) 645–651
- Lee, L.-H., see Lee, Y.-T. (6) 815–822
- Lee, Y.-T., H.-M. Liu, L.-H. Lee, C.-J. Liu, J.-S. Lin, T.-C. Chao, W.-F. Tzeng and T.-J. Chiou, The polymorphism of CAG repeats in the androgen receptor gene and breast cancer mortality (6) 815–822
- Leeming, D.J., see Bager, C.L. (6) 783–788
- Li, B., see Wang, X. (5) 663–668
- Li, C., see Sun, M. (1) 33–40
- Li, D., see Liu, C. (6) 735–743
- Li, H., see Zhao, Y. (5) 677–683
- Li, H., X. Zhou, J. Zhu, W. Cheng, W. Zhu, Y. Shu and P. Liu, MiR-4728-3p could act as a marker of Her2 status (6) 807–814
- Li, J. and F. Wei, Retrospective analysis of TGF- β 1 expression in patients with thyroidectomy (5) 693–698
- Li, J., see Cao, X. (6) 717–723
- Li, J., see Chen, G. (6) 833–841
- Li, J., see Gu, W. (3) 249–258
- Li, J., see Zhou, J. (3) 325–331
- Li, L., see Han, B. (3) 267–280
- Li, L., see Wei, Y. (3) 235–248
- Li, L.-P., see Li, Y.-S. (4) 375–380
- Li, T., see Han, L. (3) 289–297
- Li, W., see Chen, Z. (4) 467–475
- Li, W., see Lian, L. (6) 899–907
- Li, W., see Sun, M. (1) 33–40
- Li, W., see Wang, X. (5) 663–668
- Li, X., see Bai, J. (5) 599–608
- Li, X., see Jiang, Z. (4) 381–389
- Li, X.-L., see Lian, L. (6) 899–907
- Li, Y., see Liu, Q. (1) 65–78
- Li, Y., see Wang, Y. (5) 635–643
- Li, Y., Y. Xu, C. Yu and W. Zuo, Associations of miR-146a and miR-146b expression and breast cancer in very young women (6) 881–887
- Li, Y.-S., Y.-Z. Chen, X.-B. Guo, X. Liu and L.-P. Li, VEZT as a novel independent prognostic factor in gastric cancer (4) 375–380
- Li, Z., see K. Wang, (1) 89–97
- Li, H., see K. Wang, (1) 89–97
- Lian, L., Y.-Y. Xia, C. Zhou, X.-M. Shen, X.-L. Li, S.-G. Han, Y. Zheng, Z.-Q. Mao, F.-R. Gong, M.-Y. Wu, K. Chen, M. Tao and W. Li, Application of platelet/lymphocyte and neutrophil/lymphocyte ratios in early diagnosis and prognostic prediction in patients with resectable gastric cancer (6) 899–907

- Liang, H., see Hou, Y.-C. (5) 567–573
 Liang, H., see Xie, X.-M. (3) 259–265
 Liao, F., see Zhao, Y. (5) 677–683
 Lin, J.-S., see Lee, Y.-T. (6) 815–822
 Liu, C., see Yang, J. (2) 205–211
 Liu, C., see Zheng, C. (6) 889–897
 Liu, C., Z. Yang, D. Li, Z. Liu, X. Miao, L. Yang, Q. Zou and Y. Yuan, Overexpression of B2M and loss of ALK7 expression are associated with invasion, metastasis, and poor-prognosis of the pancreatic ductal adenocarcinoma (6) 735–743
 Liu, C.-J., see Lee, Y.-T. (6) 815–822
 Liu, D., see Shan, L. (1) 47–56
 Liu, D., see Song, Y. (5) 591–597
 Liu, H., see Bai, J. (5) 599–608
 Liu, H., see He, Y. (5) 645–651
 Liu, H., see K. Wang, (1) 89–97
 Liu, H., see Zhu, H. (6) 909–913
 Liu, H.-M., see Lee, Y.-T. (6) 815–822
 Liu, J., see Wang, Y. (2) 171–180
 Liu, J., see Zheng, H. (5) 525–534
 Liu, P., see Li, H. (6) 807–814
 Liu, Q., see Nuerrula, Y. (4) 485–491
 Liu, Q., Z. Yu, Y. Xiang, N. Wu, L. Wu, B. Xu, L. Wang, P. Yang, Y. Li and L. Bai, Prognostic and predictive significance of thymidylate synthase protein expression in non-small cell lung cancer: A systematic review and meta-analysis (1) 65–78
 Liu, T., see Sun, P. (4) 391–396
 Liu, W., see Chen, Z. (4) 467–475
 Liu, W., see Jiao, S. (2) 115–123
 Liu, X., see Li, Y.-S. (4) 375–380
 Liu, Y., see Tian, T. (4) 425–432
 Liu, Z., see Liu, C. (6) 735–743
 Lokshin, A.E., see Goufman, E.I. (3) 281–287
 Lopez, C., see Zapatero, A. (1) 41–46
 Lorincz, A.T., see Brentnall, A.R. (5) 669–675
 Lu, J., see Wang, Y. (5) 635–643
 Lu, M., L. Zhou, X. Zheng, Y. Quan, X. Wang, X. Zhou and J. Ren, A novel molecular marker of breast cancer stem cells identified by cell-SELEX method (2) 163–170
 Luna-Aguirre, C.M., M. de la Luz Martinez-Fierro, F. Mar-Aguilar, I. Garza-Veloz, V. Treviño-Alvarado, A. Rojas-Martinez, J.C. Jaime-Perez, G.I. Malagon-Santiago, C.H. Gutierrez-Aguirre, O. Gonzalez-Llano, R. Salazar-Riojas, A. Hidalgo-Miranda, H.G. Martinez-Rodriguez, D. Gomez-Almaguer and R. Ortiz-Lopez, Circulating microRNA expression profile in B-cell acute lymphoblastic leukemia (3) 299–310
 Lund, S.P., see Maragh, S. (6) 763–773
 Lundin, C., see Franklin, O. (1) 1–10
 Luo, B., see Zhou, J. (3) 325–331
 Lv, S., see Wang, Y. (5) 635–643
 Ma, H., see Wang, R. (1) 27–32
 Ma, J., see Gu, W. (3) 249–258
 Ma, S.-G., see Zhu, H. (6) 909–913
 Ma, Z., see Sun, P. (4) 391–396
 Mahdi, A.A., see Singh, P.K. (2) 125–131
 Majsterek, I., see Kabzinski, J. (4) 413–423
 Malagon-Santiago, G.I., see Luna-Aguirre, C.M. (3) 299–310
 Malekzadeh, R., see Ghanbari, R. (2) 189–195
 Malisic, E.J., A.M. Krivokuca, I.Z. Boljevic and R.N. Jankovic, Impact of *RAD51* G135C and *XRCC1* Arg399Gln polymorphisms on ovarian carcinoma risk in Serbian women (5) 685–691
 Małusecka, E., see Mazurek, A. (4) 515–524
 Mangold, L., see Maragh, S. (6) 763–773
 Mao, Z.-Q., see Lian, L. (6) 899–907
 Maragh, S., R.W. Veltri, S.P. Lund, L. Mangold, S. Isharwal, C.S. Christudass, A.W. Partin, E.B. Humphreys, L. Sorbara, S. Srivastava and P.D. Wagner, Evaluation of two mitochondrial DNA biomarkers for prostate cancer detection (6) 763–773
 Mar-Aguilar, F., see Luna-Aguirre, C.M. (3) 299–310
 Margery, J., see Raphael, J. (2) 151–156
 Martinez-Rodriguez, H.G., see Luna-Aguirre, C.M. (3) 299–310
 Masood, N., A. Mubashar and A. Yasmin, Epidemiological factors related to *GSTM1* and *GSTT1* genes deletion in colon and rectum cancers: A case-control study (5) 583–589
 Masoodi, S.R., see Khan, M.S. (4) 459–465
 Massard, C., see Raphael, J. (2) 151–156
 Matsui, Y., see Nakashima, M. (4) 357–364
 Mazurek, A., M. Pierzyna, M. Giglok, U. Dworzecka, R. Suwiński and E. Małusecka, Quantification of concentration and assessment of EGFR mutation in circulating DNA (4) 515–524
 Mei, J., see He, Y. (5) 645–651
 Meng, X., see Dou, X. (2) 181–188
 Mentese, A., see Erkut, N. (5) 559–565
 Mhaidat, N.M., K.H. Alzoubi, N. Almomani and O.F. Khabour, Expression of glucose regulated protein 78 (GRP78) determines colorectal cancer response to chemotherapy (2) 197–203
 Miao, L., see Wang, R. (1) 27–32
 Miao, X., see Liu, C. (6) 735–743

- Milovanović, J., see Rabi, Z.A. (6) 745–754
- Miyata, Y., K. Kumagai, T. Nagaoka, K. Kitaura, G. Kaneda, H. Kanazawa, S. Suzuki, Y. Hamada and R. Suzuki, Clinicopathological significance and prognostic value of Wilms' tumor gene expression in colorectal cancer (6) 789–797
- Mocevicus, P., see Jakubauskiene, E. (5) 575–581
- Mokarram, P., see Naghibalhossaini, F. (3) 227–233
- Mokhdomi, T.A., see Danish, Q. (5) 619–633
- Morente, M., see Zapatero, A. (1) 41–46
- Morrissey, M., see Sonkin, D. (1) 79–87
- Mosakhani, N., see Ghanbari, R. (2) 189–195
- Mowla, S.J., see Ayremlou, N. (6) 851–860
- Mowla, S.J., see Ghanbari, R. (2) 189–195
- Mozdarani, H., see Ayremlou, N. (6) 851–860
- Mu, D., see Dou, X. (2) 181–188
- Mu, Y., see Wang, Y. (5) 635–643
- Mubashar, A., see Masood, N. (5) 583–589
- Mudassar, S., see Khan, M.S. (4) 459–465
- Munz, M., see Tsaour, I. (3) 311–316
- Murad, S., see Gul, S. (5) 551–557
- Murakumo, Y., see Yanagisawa, N. (4) 365–374
- Nagaoka, T., see Miyata, Y. (6) 789–797
- Naghibalhossaini, F., P. Mokarram, E. Khalili and S. Naghibalhossaini, *DNMT3b* -149C/T promoter variants and methylation of colorectal cancer-associated genes (3) 227–233
- Naghibalhossaini, S., see Naghibalhossaini, F. (3) 227–233
- Nakada, N., see Yanagisawa, N. (4) 365–374
- Nakamura, E., see Nakashima, M. (4) 357–364
- Nakashima, M., Y. Matsui, T. Kobayashi, R. Saito, S. Hatahira, K. Kawakami, E. Nakamura, H. Nishiyama and O. Ogawa, Urine CXCL1 as a biomarker for tumor detection and outcome prediction in bladder cancer (4) 357–364
- Naredi, P., see Franklin, O. (1) 1–10
- Nie, C., see Xia, Z. (5) 707–716
- Nie, J., see Yang, J. (2) 205–211
- Nieto, S., see Zapatero, A. (1) 41–46
- Nikolić-Vukosavljević, D., see Rabi, Z.A. (6) 745–754
- Nishiyama, H., see Nakashima, M. (4) 357–364
- Nouraei, N., see Ghanbari, R. (2) 189–195
- Nuerrula, Y., M. Rexiati, Q. Liu and Y.-J. Wang, Differential expression and clinical significance of serum protein among patients with clear-cell renal cell carcinoma (4) 485–491
- Ogawa, O., see Nakashima, M. (4) 357–364
- Öhlund, D., see Franklin, O. (1) 1–10
- Oikonomou, K.G., see Vlachostergios, P.J. (6) 725–734
- Okayasu, I., see Yanagisawa, N. (4) 365–374
- Olandoski, M., see Schussel, J.L. (1) 11–17
- Öman, M., see Franklin, O. (1) 1–10
- Oppermann, E., see Tsaour, I. (3) 311–316
- Ordu, C., see Kilic, L. (4) 405–411
- Orem, A., see Erkut, N. (5) 559–565
- Ortiz-Lopez, R., see Luna-Aguirre, C.M. (3) 299–310
- Ortiz-Lopez, R., see Luna-Aguirre, C.M. (3) 299–310
- Ounissi, D., see Amara, S. (6) 869–879
- Ouyang, H., Z. Guo, Z. Cheng and Y. Guo, siRNA-mediated knockdown of *JUB* expression suppresses the proliferation of glioblastoma cells (4) 477–484
- Ozbas, H.M., see Erkut, N. (5) 559–565
- Palmer, M., see Sonkin, D. (1) 79–87
- Pan, C., see Dai, S.-L. (4) 507–513
- Pan, L., see Zheng, H. (5) 525–534
- Pan, Y.-M., see Wang, X.-L. (6) 799–805
- Pandith, A.A., see Khan, M.S. (4) 459–465
- Parsafar, S., S. Hematti, F. Ghorbani, F. Safari and M. Tavassoli, Polymorphic GT Dinucleotide repeat in the *PIK3CA* gene and risk of colorectal cancer (4) 397–403
- Partin, A.W., see Maragh, S. (6) 763–773
- Peciuliene, I., see Jakubauskiene, E. (5) 575–581
- Pedruzzi, P.A.G., see Schussel, J.L. (1) 11–17
- Pektasides, D., see Aravantinos, G. (6) 843–850
- Peng, B., see He, Q. (6) 823–831
- Peng, C., see Jiao, S. (2) 115–123
- Peng, L., see Wu, Z.Y. (5) 535–542
- Peng, Y.-G., see Zhu, H. (6) 909–913
- Perelmuter, V.M., see Kaigorodova, E.V. (2) 143–150
- Pérez-Sayáns, M., J.M. Suárez-Peñaranda, E.P. Iruegas, M.R. de Almeida, F. Barros-Angueira, M.G. Torreira and A. García-García, p21^{Waf1/CIP1} is a poor diagnostic and prognostic marker for OSCC although its expression increases in patients with N1 regional metastasis (1) 19–26
- Perfecto-Avalos, Y., see Gutiérrez-Monreal, M.A. (5) 699–705
- Pierzyna, M., see Mazurek, A. (4) 515–524
- Pinzon-Ortiz, M., see Sonkin, D. (1) 79–87
- Planchard, D., see Raphael, J. (2) 151–156
- Poustchi, H., see Ghanbari, R. (2) 189–195
- Przybyłowska, K., see Kabzinski, J. (4) 413–423
- Qing, Y., see Yang, J. (2) 205–211
- Quan, Y., see Lu, M. (2) 163–170

- Rabi, Z.A., N. Todorović-Raković, T. Vujasinović, J. Milovanović and D. Nikolić-Vukosavljević, Markers of progression and invasion in short term follow up of untreated breast cancer patients (6) 745–754
- Radimerski, T., see Sonkin, D. (1) 79–87
- Rai, A.K., see Sarma, A. (4) 501–505
- Rajamani, S., see Askeland, E.J. (6) 861–867
- Rajender, S., see Sankhwar, M. (4) 349–355
- Rakobradovic, J., see Krivokuca, A. (6) 775–781
- Rao, Q., see Wang, Y. (2) 171–180
- Raphael, J., C. Massard, I.Y. Gong, F. Farace, J. Margery, F. Billiot, A. Hollebecque, B. Besse, J.-C. Soria and D. Planchard, Detection of circulating tumour cells in peripheral blood of patients with malignant pleural mesothelioma (2) 151–156
- Rather, T.A., see Khan, M.S. (4) 459–465
- Regnier, C.H., see Sonkin, D. (1) 79–87
- Ren, J., see Lu, M. (2) 163–170
- Rexiati, M., see Nuerrula, Y. (4) 485–491
- Rizk, A., see Abdel Salam, R. (4) 441–458
- Rizos, S., see Dikaiakos, P. (2) 157–162
- Rojas-Martinez, A., see Luna-Aguirre, C.M. (3) 299–310
- Rong, X., see Sonkin, D. (1) 79–87
- Ruan, J., see Zheng, H. (5) 525–534
- Safari, F., see Parsafar, S. (4) 397–403
- Saito, R., see Nakashima, M. (4) 357–364
- Saleh, A.M., see Aljada, A. (5) 653–661
- Sangale, Z., see Askeland, E.J. (6) 861–867
- Sankhwar, M., S.N. Sankhwar, A. Abhishek and S. Rajender, Clinical significance of the VEGF level in urinary bladder carcinoma (4) 349–355
- Sankhwar, S.N., see Bansal, N. (4) 339–348
- Sankhwar, S.N., see Sankhwar, M. (4) 349–355
- Sarma, A., M. Hazarika, D. Das, A.K. Rai, J.D. Sharma, C. Bhuyan and A.C. Kataki, Expression of aberrant CD markers in Acute leukemia: A study of 100 cases with immunophenotyping by multi-parameter flowcytometry (4) 501–505
- Sassi, L.M., see Schussel, J.L. (1) 11–17
- Satoh, T., see Yanagisawa, N. (4) 365–374
- Schilling, D., see Tsaour, I. (3) 311–316
- Schlegel, R., see Sonkin, D. (1) 79–87
- Schussel, J.L., L.P. Kalinke, L.M. Sassi, B.V. de Oliveira, P.A.G. Pedruzzi, M. Olandoski, L.E. Alvares, G.P. Garlet and P.C. Trevilatto, Expression and epigenetic regulation of *DACT1* and *DACT2* in oral squamous cell carcinoma (1) 11–17
- Scibior-Bentkowska, D., see Brentnall, A.R. (5) 669–675
- Scott, S.-P., see Gutiérrez-Monreal, M.A. (5) 699–705
- Sen, F.K., see Kilic, L. (4) 405–411
- Serilmez, M., see Kilic, L. (4) 405–411
- Shamsa, H.B., see Aljada, A. (5) 653–661
- Shan, L., Q. Ji, G. Cheng, J. Xia, D. Liu, C. Wu, B. Zhu and Y. Ding, Diagnostic value of circulating miR-21 for colorectal cancer: A meta-analysis (1) 47–56
- Shang, L., see Shi, Z.-Z. (6) 755–761
- Shao, B., see K. Wang, (1) 89–97
- Shao, L., see Tian, T. (4) 425–432
- Sharma, J.D., see Sarma, A. (4) 501–505
- Shen, X.-M., see Lian, L. (6) 899–907
- Shi, F., see Shi, Z.-Z. (6) 755–761
- Shi, W., see Wang, Y. (2) 171–180
- Shi, Y., see Zhou, J. (3) 325–331
- Shi, Z.-L., see Dai, S.-L. (4) 507–513
- Shi, Z.-Z., L. Shang, Y.-Y. Jiang, F. Shi, X. Xu, M.-R. Wang and J.-J. Hao, Identification of genomic biomarkers associated with the clinicopathological parameters and prognosis of esophageal squamous cell carcinoma (6) 755–761
- Shigetomi, H., see Yoshimoto, C. (4) 493–499
- Shiraishi, A., see Hiura, K. (4) 433–440
- Shu, Y., see Li, H. (6) 807–814
- Siewiński, M., see Kilar, E. (1) 99–102
- Singh, P.K., J. Bogra, G. Chandra, M.K. Ahmad, R. Gupta, V. Kumar, A. Jain and A.A. Mahdi, Association of TNF- α (-238 and -308) promoter polymorphisms with susceptibility of oral squamous cell carcinoma in North Indian population (2) 125–131
- Sioziou, A., see Aravantinos, G. (6) 843–850
- Sirulnik, A., see Sonkin, D. (1) 79–87
- Skiba, T., see Kilar, E. (1) 99–102
- Skrajnowska, D., see Bobrowska-Korczak, B. (2) 133–142
- Slonimskaya, E.M., see Kaigorodova, E.V. (2) 143–150
- Smith, V., see Bager, C.L. (6) 783–788
- Song, C., see Xia, Z. (5) 707–716
- Song, Q., see Jiang, Z. (4) 381–389
- Song, X., see Dou, X. (2) 181–188
- Song, Y., D. Liu and G. He, TKTL1 and p63 are biomarkers for the poor prognosis of gastric cancer patients (5) 591–597
- Sonkin, D., M. Palmer, X. Rong, K. Horrigan, C.H. Regnier, C. Fanton, J. Holash, M. Pinzon-Ortiz, M. Squires, A. Sirulnik, T. Radimerski, R. Schlegel, M. Morrissey and Z.A. Cao, The identification and characterization of a STAT5 gene signature in hematologic malignancies (1) 79–87

- Sonmez, M., see Erkut, N. (5) 559–565
- Sorbara, L., see Maragh, S. (6) 763–773
- Soria, J.-C., see Raphael, J. (2) 151–156
- Squires, M., see Sonkin, D. (1) 79–87
- Srivastava, S., see Maragh, S. (6) 763–773
- Stenzl, A., see Tsaur, I. (3) 311–316
- Stone, S., see Askeland, E.J. (6) 861–867
- Suárez-Peñaranda, J.M., see Pérez-Sayáns, M. (1) 19–26
- Sultan, A., see Gul, S. (5) 551–557
- Sumer, A., see Erkut, N. (5) 559–565
- Sun, D., see Sun, P. (4) 391–396
- Sun, M., S. Fang, W. Li, C. Li, L. Wang, F. Wang and Y. Wang, Associations of miR-146a and miR-146b expression and clinical characteristics in papillary thyroid carcinoma (1) 33–40
- Sun, P., D. Sun, X. Wang, T. Liu, Z. Ma and L. Duan, miR-206 is an independent prognostic factor and inhibits tumor invasion and migration in colorectal cancer (4) 391–396
- Sun, Q., see Chen, G. (6) 833–841
- Sun, Y., see Gu, W. (3) 249–258
- Sund, M., see Franklin, O. (1) 1–10
- Suwiński, R., see Mazurek, A. (4) 515–524
- Suzuki, C., see Hiura, K. (4) 433–440
- Suzuki, R., see Miyata, Y. (6) 789–797
- Suzuki, S., see Miyata, Y. (6) 789–797
- Takamura, K., see Hiura, K. (4) 433–440
- Tang, H., see Jiao, S. (2) 115–123
- Tang, W., see Xu, L. (1) 57–63
- Tao, M., see Lian, L. (6) 899–907
- Tarabanovskaya, N.A., see Kaigorodova, E.V. (2) 143–150
- Tas, F., see Kilic, L. (4) 405–411
- Tavassoli, M., see Parsafar, S. (4) 397–403
- Theodoropoulos, G.E., see Aravantinos, G. (6) 843–850
- Theodoropoulos, G.E., see Dikaiakos, P. (2) 157–162
- Tian, H., see Yang, J. (2) 205–211
- Tian, T., X. Gu, B. Zhang, Y. Liu, C. Yuan, L. Shao, Y. Guo and K. Fan, Increased circulating CD14(+)/HLA-DR-/low myeloid-derived suppressor cells are associated with poor prognosis in patients with small-cell lung cancer (4) 425–432
- Tikhonova, N.B., see Goufman, E.I. (3) 281–287
- Todorović-Raković, N., see Rabi, Z.A. (6) 745–754
- Tokarz, A., see Bobrowska-Korcza, B. (2) 133–142
- Topbas, M., see Erkut, N. (5) 559–565
- Torreira, M.G., see Pérez-Sayáns, M. (1) 19–26
- Treviño-Alvarado, V., see Luna-Aguirre, C.M. (3) 299–310
- Trevilatto, P.C., see Schussel, J.L. (1) 11–17
- Tsaur, I., J. Hennenlotter, E. Oppermann, M. Munz, U. Kuehs, A. Stenzl and D. Schilling, PCA3 and PSA gene activity correlates with the true tumor cell burden in prostate cancer lymph node metastases (3) 311–316
- Tzeng, W.-F., see Lee, Y.-T. (6) 815–822
- Vasiljevic, N., see Brentnall, A.R. (5) 669–675
- Veltri, R.W., see Maragh, S. (6) 763–773
- Vicente, F.G., see Zapatero, A. (1) 41–46
- Vilkaitis, G., see Jakubauskiene, E. (5) 575–581
- Villela, L., see Gutiérrez-Monreal, M.A. (5) 699–705
- Vilys, L., see Jakubauskiene, E. (5) 575–581
- Vlachostergios, P.J., K.G. Oikonomou, E. Gibilaro and G. Apergis, Elevated lactic acid is a negative prognostic factor in metastatic lung cancer (6) 725–734
- Vujasinović, T., see Rabi, Z.A. (6) 745–754
- Wagner, P.D., see Maragh, S. (6) 763–773
- Wang, D., see Wang, Y. (5) 635–643
- Wang, F., see Sun, M. (1) 33–40
- Wang, J., see Gu, W. (3) 249–258
- Wang, J., see Wang, Y. (3) 213–218
- Wang, J., see Zhou, J. (3) 325–331
- Wang, K., see K. Wang, (1) 89–97
- Wang, L., see Liu, Q. (1) 65–78
- Wang, L., see Sun, M. (1) 33–40
- Wang, M., see K. Wang, (1) 89–97
- Wang, M., see Zhao, Y. (5) 677–683
- Wang, M.-R., see Shi, Z.-Z. (6) 755–761
- Wang, R., L. Zhu, Y. Zhang, L. Miao, H. Ma, H. Yuan and N. Chen, Genetic variants at 6p21.1 are associated with head and neck cancer in Chinese Han population (1) 27–32
- Wang, R., see Dou, X. (2) 181–188
- Wang, S.M., see Wu, Z.Y. (5) 535–542
- Wang, T., F. Ji, Z. Dai, Y. Xie and D. Yuan, Increased expression of microRNA-191 as a potential serum biomarker for diagnosis and prognosis in human osteosarcoma (5) 543–550
- Wang, W., see Franklin, O. (1) 1–10
- Wang, X., J. Cui, J. Gu, H. He, B. Li and W. Li, Plasma 25-hydroxyvitamin D deficiency is associated with the risk of non-small cell lung cancer in a Chinese population (5) 663–668
- Wang, X., see Lu, M. (2) 163–170
- Wang, X., see Sun, P. (4) 391–396

- Wang, X.-L., Y.-Y. Wang, H.-D. He, X. Xie, Z.-J. Yu and Y.-M. Pan, Association of plasma intermedin levels with progression and metastasis in men after radical prostatectomy for localized prostatic cancer (6) 799–805
- Wang, Y., J. Lu, X. Zhao, Y. Feng, S. Lv, Y. Mu, D. Wang, H. Fu, Y. Chen and Y. Li, Prognostic significance of Ubiquilin1 expression in invasive breast cancer (5) 635–643
- Wang, Y., J. Wang and Y. Huang, MicroRNAs as new biomarkers for human papilloma virus related head and neck cancers (3) 213–218
- Wang, Y., see Sun, M. (1) 33–40
- Wang, Y., Y. Gao, W. Shi, D. Zhai, Q. Rao, X. Jia, J. Liu, X. Jiao and Z. Du, Profiles of differential expression of circulating microRNAs in hepatitis B virus-positive small hepatocellular carcinoma (2) 171–180
- Wang, Y.-J., see Nuerrula, Y. (4) 485–491
- Wang, Y.-Y., see Wang, X.-L. (6) 799–805
- Watanabe, Y., see Hiura, K. (4) 433–440
- Wei, F., see Li, J. (5) 693–698
- Wei, Y., L. Li and J. Gao, The association between two common polymorphisms (miR-146a rs2910164 and miR-196a2 rs11614913) and susceptibility to gastric cancer: A meta-analysis (3) 235–248
- Wen, J., see Zhou, J. (3) 325–331
- Weslati, M., see Amara, S. (6) 869–879
- Willumsen, N., see Bager, C.L. (6) 783–788
- Wu, C., see Shan, L. (1) 47–56
- Wu, H., see Chen, Z. (4) 467–475
- Wu, L., see He, Q. (6) 823–831
- Wu, L., see Liu, Q. (1) 65–78
- Wu, M., see Jiao, S. (2) 115–123
- Wu, M.-Y., see Lian, L. (6) 899–907
- Wu, N., see Liu, Q. (1) 65–78
- Wu, S., see Han, B. (3) 267–280
- Wu, W.-P., see Hou, Y.-C. (5) 567–573
- Wu, W.-P., see Xie, X.-M. (3) 259–265
- Wu, X., see Zhao, Y. (5) 677–683
- Wu, X., see Zhou, J. (3) 325–331
- Wu, Z.Y., S.M. Wang, Z.H. Chen, S.X. Hu, K. Huang, B.J. Huang, J.L. Du, C.M. Huang, L. Peng, Z.X. Jian and G. Zhao, MiR-204 regulates HMGA2 expression and inhibits cell proliferation in human thyroid cancer (5) 535–542
- Xia, J., see Shan, L. (1) 47–56
- Xia, Y.-Y., see Lian, L. (6) 899–907
- Xia, Z., F. Duan, C. Jing, Z. Guo, C. Nie and C. Song, Quantitative assessment of the association between *DNMT3B* -579G>T polymorphism and cancer risk (5) 707–716
- Xiang, Y., see Liu, Q. (1) 65–78
- Xiao, H., see He, Y. (5) 645–651
- Xiao, L., see He, Q. (6) 823–831
- Xie, J., see Zheng, C. (6) 889–897
- Xie, M., see Zhou, J. (3) 325–331
- Xie, R., see Han, B. (3) 267–280
- Xie, X., see Jiao, S. (2) 115–123
- Xie, X., see Wang, X.-L. (6) 799–805
- Xie, X.-M., J.-Y. Deng, Y.-C. Hou, J.-L. Cui, W.-P. Wu, G.-G. Ying, Q.-P. Dong, X.-S. Hao and H. Liang, Evaluating the clinical feasibility: The direct bisulfite genomic sequencing for examination of methylated status of E3 ubiquitin ligase RNF180 DNA promoter to predict the survival of gastric (3) 259–265
- Xie, X.-M., see Hou, Y.-C. (5) 567–573
- Xie, Y., see Wang, T. (5) 543–550
- Xu, B., see He, Q. (6) 823–831
- Xu, B., see Liu, Q. (1) 65–78
- Xu, C., see He, Q. (6) 823–831
- Xu, L. and W. Tang, The associations of nucleotide polymorphisms in mir-196a2, mir-146a, mir-149 with lung cancer risk (1) 57–63
- Xu, N., see Askeland, E.J. (6) 861–867
- Xu, X., see Dou, X. (2) 181–188
- Xu, X., see Shi, Z.-Z. (6) 755–761
- Xu, Y., see Li, Y. (6) 881–887
- Xue, Q., see Chen, G. (6) 833–841
- Yamamoto, M., see Hiura, K. (4) 433–440
- Yan, H., see Dou, X. (2) 181–188
- Yanagisawa, N., T. Satoh, K. Hana, M. Ichinoe, N. Nakada, H. Endou, I. Okayasu and Y. Murakumo, L-amino acid transporter 1 may be a prognostic marker for local progression of prostatic cancer under expectant management (4) 365–374
- Yang, F., see Yang, J. (2) 205–211
- Yang, J., F. Yang, J. Nie, X. Zou, H. Tian, Y. Qing and C. Liu, Evaluation of AnnexinA2 as a novel diagnostic serum biomarker for lung cancer (2) 205–211
- Yang, J., see Han, L. (3) 289–297
- Yang, K.-X., see Dai, S.-L. (4) 507–513
- Yang, L., see Liu, C. (6) 735–743
- Yang, P., see Liu, Q. (1) 65–78
- Yang, S., see Jiang, Z. (4) 381–389
- Yang, S.-Y., see Dai, S.-L. (4) 507–513
- Yang, Z., see Liu, C. (6) 735–743
- Yanowski, K., see Krivokuca, A. (6) 775–781
- Yasmin, A., see Masood, N. (5) 583–589
- Yildirim, M.E., see Kaynar, M. (3) 317–323

- Yildiz, I., see Kilic, L. (4) 405–411
- Ying, G.-G., see Xie, X.-M. (3) 259–265
- Yoshimoto, C., T. Iwabuchi, H. Shigetomi and H. Kobayashi, Cyst fluid iron-related compounds as useful markers to distinguish malignant transformation from benign endometriotic cysts (4) 493–499
- Yu, C., see Li, Y. (6) 881–887
- Yu, F., see He, Q. (6) 823–831
- Yu, J., see Cao, X. (6) 717–723
- Yu, X.-L., see Zhang, J. (5) 609–617
- Yu, Z., see Liu, Q. (1) 65–78
- Yu, Z.-J., see Wang, X.-L. (6) 799–805
- Yuan, C., see Tian, T. (4) 425–432
- Yuan, D., see Wang, T. (5) 543–550
- Yuan, H., see Wang, R. (1) 27–32
- Yuan, Y., see Liu, C. (6) 735–743
- Zapatero, A., M. Morente, C.M. de Vidales, M. Adrados, C. Lopez, S. Nieto, M.J.A. González, R. Arellano, A.C. Conde and F.G. Vicente, HIF1A expression in localized prostate cancer treated with dose escalation radiation therapy (1) 41–46
- Zavyalova, M.V., see Kaigorodova, E.V. (2) 143–150
- Zeng, R., see Jiang, Z. (4) 381–389
- Zhai, D., see Wang, Y. (2) 171–180
- Zhang, B., see Cao, X. (6) 717–723
- Zhang, B., see Tian, T. (4) 425–432
- Zhang, D., see Chen, Z. (4) 467–475
- Zhang, J., see Jiang, Z. (4) 381–389
- Zhang, J., X.-L. Yu, G.-F. Zheng and F. Zhao, *DAPK* promoter methylation status correlates with tumor metastasis and poor prognosis in patients with non-small cell lung cancer (5) 609–617
- Zhang, L., see Zhao, Y. (5) 677–683
- Zhang, R.-P., see Hou, Y.-C. (5) 567–573
- Zhang, S., see Chen, Z. (4) 467–475
- Zhang, Y., see Cao, X. (6) 717–723
- Zhang, Y., see Wang, R. (1) 27–32
- Zhang, Y., see Zhao, J. (3) 219–226
- Zhang, Z., see Bai, J. (5) 599–608
- Zhao, F., see Zhang, J. (5) 609–617
- Zhao, G., see He, Q. (6) 823–831
- Zhao, G., see Wu, Z.Y. (5) 535–542
- Zhao, G., see Zhao, J. (3) 219–226
- Zhao, J., see He, Q. (6) 823–831
- Zhao, J., Y. Zhang and G. Zhao, Emerging role of microRNA-21 in colorectal cancer (3) 219–226
- Zhao, P., see Zheng, H. (5) 525–534
- Zhao, R., see Cao, X. (6) 717–723
- Zhao, X., see Wang, Y. (5) 635–643
- Zhao, Y., M. Wang, C. Cui, L. Zhang, F. Liao, H. Li and X. Wu, Significance of combined tests of serum golgi glycoprotein 73 and other biomarkers in diagnosis of small primary hepatocellular carcinoma (5) 677–683
- Zhao, Y., see Cao, X. (6) 717–723
- Zheng, C., R. Chen, J. Xie, C. Liu, Z. Jin and C. Jin, Immunohistochemical expression of Notch1, Jagged1, NF- κ B and MMP-9 in colorectal cancer patients and the relationship to clinicopathological parameters (6) 889–897
- Zheng, G.-F., see Zhang, J. (5) 609–617
- Zheng, H., J. Ruan, P. Zhao, S. Chen, L. Pan and J. Liu, Heparanase is involved in proliferation and invasion of ovarian cancer cells (5) 525–534
- Zheng, L., see He, Q. (6) 823–831
- Zheng, P., see Chen, Z. (4) 467–475
- Zheng, X., see Gu, W. (3) 249–258
- Zheng, X., see Lu, M. (2) 163–170
- Zheng, Y., see Jiang, Z. (4) 381–389
- Zheng, Y., see Lian, L. (6) 899–907
- Zhou, C., see Lian, L. (6) 899–907
- Zhou, J., M. Xie, H. He, Y. Shi, B. Luo, G. Gong, J. Li, J. Wang, X. Wu and J. Wen, Increases urinary HMGA1 in serous epithelial ovarian cancer patients (3) 325–331
- Zhou, J., see Dai, S.-L. (4) 507–513
- Zhou, L., see Lu, M. (2) 163–170
- Zhou, P., see He, Q. (6) 823–831
- Zhou, X., see Chen, Z. (4) 467–475
- Zhou, X., see Li, H. (6) 807–814
- Zhou, X., see Lu, M. (2) 163–170
- Zhou, Y., see Han, L. (3) 289–297
- Zhu, B., see Shan, L. (1) 47–56
- Zhu, H., Y.-G. Peng, S.-G. Ma and H. Liu, *TPO* gene mutations associated with thyroid carcinoma: Case report and literature review (6) 909–913
- Zhu, J., see He, Q. (6) 823–831
- Zhu, J., see Li, H. (6) 807–814
- Zhu, K., see Dou, X. (2) 181–188
- Zhu, L., see Han, B. (3) 267–280
- Zhu, L., see Wang, R. (1) 27–32
- Zhu, S., B. Shao, Y. Hao, Z. Li, H. Liu, H. Li. M. Wang and K. Wang, No association of single nucleotide polymorphisms involved in GHRL and GHSR with cancer risk: A meta-analysis (1) 89–97
- Zhu, W., see Li, H. (6) 807–814
- Zhuang, D., see He, Q. (6) 823–831
- Zografos, G., see Dikaiakos, P. (2) 157–162
- Zou, Q., see Liu, C. (6) 735–743
- Zou, X., see Yang, J. (2) 205–211
- Zuo, W., see Li, Y. (6) 881–887